FilingReader Intelligence
Shanghai Pharmaceuticals faces management change, unlocks share potential
April 7, 2025 at 07:03 AM UTC•By FilingReader AI
Shanghai Pharmaceuticals Holding (SSE:601607) is undergoing a series of strategic changes, as evidenced by recent announcements. Effective April 1, 2025, Mr. Li Dongming will no longer serve as Vice President of the company, or hold any positions within its subsidiaries, as his labor contract has expired and will not be renewed.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Supplementary Source Documents
Announcement of Shanghai Pharmaceuticals Holding Co., Ltd. on Issuing Restricted Shares to Specific Objects for Listing and CirculationApril 1, 2025 at 09:53 AM UTC
Shanghai Pharmaceuticals Group Co., Ltd. Announcement on the Results of the Third Exercise Period of the Reserved Stock Options under the 2019 A-Share Stock Option Incentive Plan in the First Quarter of 2025April 1, 2025 at 09:53 AM UTC
SDIC Securities Co., Ltd.'s Verification Opinion on the Issuance of Restricted Shares to Specific Targets by Shanghai Pharmaceuticals Group Co., Ltd. for Listing and CirculationApril 1, 2025 at 09:53 AM UTC
SSE:601607•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Pharmaceuticals Holding publishes news
Free account required • Unsubscribe anytime